Advances and management of solid tumors in children.
In recent years there has been a significant improvement in the survival rate of children with malignant solid tumors. With Wilms' tumor, the survival rate has risen to 80%, but a subset of these patients with unfavorable histologies and therefore a higher rate of relapse need a different strategy. For those patients with soft tissue sarcoma, brain tumors, and bone tumors the combination of preoperative chemotherapy, surgery, and radiotherapy followed by maintenance multiagent chemotherapy has resulted in a survival rate of 45% to 70%. In the case of neuroblastoma, a similar aggressive approach has not resulted in an improved survival. A different approach that uses screening of infants by urinary testing for VMA and HVA to detect earlier and potentially less malignant tumors has begun in Japan and North America in the hope that preclinical detection will reduce mortality.
Nesbit
M E
ME
Department of Pediatrics, University of Minnesota, Minneapolis 55455.
D001859:Bone Neoplasms / Q000628:therapy*; D001932:Brain Neoplasms / Q000628:therapy*; D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007680:Kidney Neoplasms / Q000628:therapy*; D008403:Mass Screening; D009447:Neuroblastoma / Q000517:prevention & control / Q000628:therapy*; D011379:Prognosis; D009396:Wilms Tumor / Q000628:therapy*